Fotemustine administered intravenously (IV) is a specific method for delivering this chemotherapy drug to treat metastatic melanoma. Here's a breakdown:
- Medication: Fotemustine, a nitrosourea alkylating agent.
- Delivery: Intravenous (IV), meaning it's injected directly into a vein through a thin tube (catheter).
- Purpose: Targets metastatic melanoma, advanced skin cancer that has spread.
Key points about Fotemustine IV:
- Administration:
- Typically given over 60 minutes.
- Solution is prepared just before use due to light sensitivity.
- Healthcare professionals take precautions to avoid exposure during administration.
- Mechanism of action: Damages DNA in cancer cells, hindering their growth and division.
- Efficacy: May improve response rates compared to some other treatments for metastatic melanoma, but doesn't necessarily extend lifespan.
Important considerations:
- Side effects: Increased risk of neutropenia (low white blood cells) and thrombocytopenia (low platelets), along with nausea, vomiting, fatigue, hair loss, and appetite loss.
- Not FDA approved in the US: Available in Europe but requires consultation with a medical professional to understand the risks and benefits compared to other options.
Remember: This information is for general knowledge only. If you're being considered for Fotemustine IV treatment for metastatic melanoma, consult a doctor to discuss the specifics of your situation and make the best course of action.